Zalutumumab is a human IgG1 monoclonal antibody directed against EGFR. Zalutumumab binds to EGFR receptor and blocks receptor binding of EGF and TGF-a, inducing apoptosis of EGFR-expressing tumor cells.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.